Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary Ann Mascelli

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Journal of Thrombosis and Thrombolysis|April 9, 2005
Antibodies to platelet factor 4/heparin are associated with elevated endothelial cell activation markers in patients with acute coronary ischemic syndromesMary Ann Mascelli, Efthymios N Deliargyris, Lakshmi V Damaraju, et al.
Annals of the New York Academy of Sciences|July 25, 2012
Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an updateNewman Yeilding, Philippe Szapary, Carrie Brodmerkel, et al.
Circulation|April 23, 2003
Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromesR Taylor Williams, Lakshmi V Damaraju, Mary Ann Mascelli, et al.
Annals of the New York Academy of Sciences|March 26, 2011
Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectivesNewman Yeilding, Philippe Szapary, Carrie Brodmerkel, et al.
Clinical Pharmacology and Therapeutics|October 24, 2024
Model-Informed Approach to Recommend Burosumab Dosing Regimens for Pediatric and Adult Patients With the Ultrarare Disease Tumor-Induced OsteomalaciaMatthew W Hruska, Lamia Sid-Otmane, Nathalie H Gosselin, et al.
The Journal of Rheumatology|April 4, 2006
A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritisRené Westhovens, Frédéric Houssiau, Johan Joly, et al.
Current Medical Research and Opinion|May 24, 2007
A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasisAlice B Gottlieb, Kevin D Cooper, Thomas S McCormick, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|April 4, 2015
A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis IIJoseph Muenzer, Christian J Hendriksz, Zheng Fan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 20, 2006
An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasisEiko Toichi, Gisela Torres, Thomas S McCormick, et al.
The Journal of Investigative Dermatology|December 22, 2004
A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasisCatharine L Kauffman, Nancy Aria, Eiko Toichi, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Journal of Thrombosis and Thrombolysis|April 9, 2005
Antibodies to platelet factor 4/heparin are associated with elevated endothelial cell activation markers in patients with acute coronary ischemic syndromesMary Ann Mascelli, Efthymios N Deliargyris, Lakshmi V Damaraju, et al.
Annals of the New York Academy of Sciences|July 25, 2012
Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an updateNewman Yeilding, Philippe Szapary, Carrie Brodmerkel, et al.
Circulation|April 23, 2003
Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromesR Taylor Williams, Lakshmi V Damaraju, Mary Ann Mascelli, et al.
Annals of the New York Academy of Sciences|March 26, 2011
Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectivesNewman Yeilding, Philippe Szapary, Carrie Brodmerkel, et al.
Clinical Pharmacology and Therapeutics|October 24, 2024
Model-Informed Approach to Recommend Burosumab Dosing Regimens for Pediatric and Adult Patients With the Ultrarare Disease Tumor-Induced OsteomalaciaMatthew W Hruska, Lamia Sid-Otmane, Nathalie H Gosselin, et al.
The Journal of Rheumatology|April 4, 2006
A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritisRené Westhovens, Frédéric Houssiau, Johan Joly, et al.
Current Medical Research and Opinion|May 24, 2007
A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasisAlice B Gottlieb, Kevin D Cooper, Thomas S McCormick, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|April 4, 2015
A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis IIJoseph Muenzer, Christian J Hendriksz, Zheng Fan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 20, 2006
An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasisEiko Toichi, Gisela Torres, Thomas S McCormick, et al.
The Journal of Investigative Dermatology|December 22, 2004
A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasisCatharine L Kauffman, Nancy Aria, Eiko Toichi, et al.
Pageof 3